Exo-r-mecamylamine formulation and use in treatment

Details Exo-r-mecamylamine formulation and use in treatment Exo-r-mecamylamine formulation and use in treatment

A - Human Necessities

01

N

A01N 33/18 (2006.01) A01N 33/02 (2006.01) A01N 33/24 (2006.01) A61K 9/06 (2006.01) A61K 9/08 (2006.01) A61K 9/22 (2006.01) A61K 9/52 (2006.01) A61K 31/015 (2006.01) A61K 31/13 (2006.01) A61P 1/04 (2006.01) A61P 1/06 (2006.01) A61P 3/02 (2006.01) A61P 9/12 (2006.01) A61P 25/02 (2006.01) A61P 25/14 (2006.01) A61P 25/16 (2006.01) A61P 25/18 (2006.01) A61P 25/22 (2006.01) A61P 25/24 (2006.01) A61P 25/28 (2006.01) A61P 25/30 (2006.01) A61P 25/32 (2006.01) A61P 25/34 (2006.01) A61P 35/00 (2006.01) A61P 37/08 (200

Patent

CA 2393442

A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorders, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

L'invention concerne une composition pharmaceutique renfermant une quantité thérapeutiquement efficace d'exo-R-mécamylamine ou un sel pharmaceutiquement acceptable correspondant, sensiblement dépourvu d'exo-R-mécamylamine, en combinaison avec un vecteur pharmaceutiquement acceptable. De préférence, la quantité est comprise entre environ 0,5 et environ 20 mg. Le traitement repose sur l'administration d'une quantité thérapeutiquement efficace d'exo-R-mécamylamine ou d'un sel pharmaceutiquement acceptable correspondant, sensiblement dépourvu d'exo-R-mécamylamine, cette quantité étant suffisante pour améliorer l'état des patients. La liste non exhaustive des états pathologiques traités est la suivante: dépendance vis-à-vis de substances (nicotine, cocaïne, alcool, amphétamines, opiacés, autres psychostimulants, et combinaisons de ces produits), désaccoutumance au tabac, traitement de la prise de poids en liaison avec cette désaccoutumance, hypertension, crise d'hypertension, syndrome de Gilles de la Tourette et autres tremblements, cancer (par exemple cancer pulmonaire à petites cellules), profil athérogène, troubles neuropsychiatriques (du type trouble bipolaire, dépression, trouble anxieux, schizophrénie, trouble épileptique, maladie de Parkinson et hyperactivité avec déficit de l'attention), syndrome de fatigue chronique, maladie de Crohn, dystonie neuro-végétative et troubles intestinaux spasmogènes.

Affiliated with

Also associated with

Rating

Exo-r-mecamylamine formulation and use in treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Exo-r-mecamylamine formulation and use in treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exo-r-mecamylamine formulation and use in treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1454127